Drug Discovery Engine | Santaris...RNA Medicines for the 21st Century

The LNA Drug Discovery Engine

In the past decade our knowledge of the human genome and the linkage between genes and diseases has increased tremendously, providing an abundance of attractive targets for pharmaceutical intervention. RNA-targeting is the most direct way to translate this genomic information into drugs, and LNA is the chemistry-of-choice for these applications.

To support its discovery and clinical development activities of novel LNA drugs, Santaris Pharma A/S has invested heavily in its drug discovery and development capabilities, bringing together scientists with experience, talent and commitment to change the field of RNA-medicines. As a result the Company now controls a Drug Discovery Engine, which can rationally design and discover potent and safe RNA-targeted drugs, quickly and cost-effectively exploiting the efficiencies of the antisense technology. It is clear that further scale-up to support large clinical trials will allow oligonucleotide drugs to be produced at prices competitive with many other advanced therapies.

Santaris Pharma a/s has completed multiple manufacturing campaigns to GMP standards on five unique oligonucleotide therapeutics and is leveraging its discovery capability against two major classes of RNAs: messengerRNA (mRNA) and microRNA(miRNAs).